Nova Mentis Life Science Corp
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing natural remedies specifically tailored for individuals on the autism spectrum; health-related foods that promote both mind and body wellness for healthy living, as well as psilocybin clinical trial for fragile X syndrome. The company has collaboration with the University … Read more
Nova Mentis Life Science Corp (NMLSF) - Total Liabilities
Latest total liabilities as of September 2025: $301.63K USD
Based on the latest financial reports, Nova Mentis Life Science Corp (NMLSF) has total liabilities worth $301.63K USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Nova Mentis Life Science Corp - Total Liabilities Trend (2005–2024)
This chart illustrates how Nova Mentis Life Science Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Nova Mentis Life Science Corp Competitors by Total Liabilities
The table below lists competitors of Nova Mentis Life Science Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SWISS RE N (SR9.SG)
STU:SR9
|
Germany | €163.21 Billion |
|
Fibon Bhd
KLSE:0149
|
Malaysia | RM4.62 Million |
|
Impera Capital S.A.
WAR:IMP
|
Poland | zł702.00K |
|
BR01
F:BR01
|
Germany | €376.68K |
|
Merchant House International Ltd
AU:MHI
|
Australia | AU$1.79 Million |
|
Medical Marijuana I
PINK:MJNA
|
USA | $17.60 Million |
Liability Composition Analysis (2005–2024)
This chart breaks down Nova Mentis Life Science Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.97 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Nova Mentis Life Science Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Nova Mentis Life Science Corp (2005–2024)
The table below shows the annual total liabilities of Nova Mentis Life Science Corp from 2005 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $489.47K | -41.85% |
| 2023-12-31 | $841.66K | +229.49% |
| 2022-12-31 | $255.44K | -39.48% |
| 2021-12-31 | $422.06K | +10.21% |
| 2020-12-31 | $382.96K | +17.81% |
| 2019-12-31 | $325.07K | +5.22% |
| 2018-12-31 | $308.95K | +94.11% |
| 2017-12-31 | $159.16K | +108.06% |
| 2016-12-31 | $76.50K | -26.59% |
| 2015-12-31 | $104.21K | -29.46% |
| 2014-12-31 | $147.74K | -53.42% |
| 2013-12-31 | $317.16K | -6.67% |
| 2012-12-31 | $339.82K | +1274.12% |
| 2011-12-31 | $24.73K | -69.15% |
| 2010-12-31 | $80.17K | -7.12% |
| 2009-12-31 | $86.32K | +26.67% |
| 2008-12-31 | $68.15K | +242.84% |
| 2007-12-31 | $19.88K | -65.23% |
| 2006-12-31 | $57.17K | +1363.19% |
| 2005-12-31 | $3.91K | -- |